Tourmaline Bio Inc. (NASDAQ:TRML) — Market Cap & Net Worth
Market Cap & Net Worth: Tourmaline Bio Inc. (TRML)
Tourmaline Bio Inc. (NASDAQ:TRML) has a market capitalization of $1.23 Billion ($1.23 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8223 globally and #2269 in its home market, demonstrating a 0.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tourmaline Bio Inc.'s stock price $47.98 by its total outstanding shares 25692268 (25.69 Million). Analyse Tourmaline Bio Inc. cash flow conversion to see how efficiently the company converts income to cash.
Tourmaline Bio Inc. Market Cap History: 2021 to 2025
Tourmaline Bio Inc.'s market capitalization history from 2021 to 2025. Data shows change from $1.74 Billion to $1.23 Billion (-8.70% CAGR).
Index Memberships
Tourmaline Bio Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.05% | #218 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #859 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.07% | #133 of 263 |
Weight: Tourmaline Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tourmaline Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tourmaline Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TRML by Market Capitalization
Companies near Tourmaline Bio Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Tourmaline Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Tourmaline Bio Inc. Historical Marketcap From 2021 to 2025
Between 2021 and today, Tourmaline Bio Inc.'s market cap moved from $1.74 Billion to $ 1.23 Billion, with a yearly change of -8.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.23 Billion | +136.59% |
| 2024 | $521.04 Million | -22.54% |
| 2023 | $672.62 Million | +477.82% |
| 2022 | $116.41 Million | -93.33% |
| 2021 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Tourmaline Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.23 Billion USD |
| MoneyControl | $1.23 Billion USD |
| MarketWatch | $1.23 Billion USD |
| marketcap.company | $1.23 Billion USD |
| Reuters | $1.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more